Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial

Table 3 Clinical outcomes in completers (n = 7)

Measurement	Baseline	6 Months	12 Months	P value 6 Months	P value 12 Months
MRSS	26.9 ± 5.4	22.7 ± 8	20.6 ± 7.7	0.02	0.01
FVC	77.4 ± 12.9	75.4 ± 12.6	71.7 ± 11.7	0.17	0.054
DLCO	72.0 ± 9.9	69.9 ± 18.1	69.3 ± 12.4	0.56	0.25
PGA	62.5 ± 10.8	40.2 ± 12.7	32.3 ±15.3	<0.01	<0.01
SHAQ	0.71 ± 0.34	0.79 ± 0.59	0.86 ± 0.66	0.86	0.74
ESR	17.2 ± 14.5	23.0 ± 22.1	22.6 ±17.7	0.19	0.1506
SF-36 MC	51.5 ± 8.2	52.8 ± 7.6	52.1 ± 5.6	0.74	0.90
SF-36 PC	43.1 ± 9.5	40.3 ± 9.5	41.7 ± 9.1	0.37	0.74

MRSS modified Rodnan skin score, FVC forced vital capacity, DLCO diffusion lung capacity of carbon monoxide, PGA physician global assessment, SHAQ scleroderma health assessment questionnaire, ESR erythrocyte sedimentation rate, SF-36 MC short form-36 health survey mental component, SF-36 PC short form-36 health survey physical component

ISSN: 1478-6362